This study was undertaken to test the hypothesis that bronchiolar damage induced by trichloroethylene (TCE) is associated with bioactivation within the Clara cells with the involvement of CYP2E1 and CYP2F2. Histopathology confirmed dose-dependent Clara cell injury and disintegration of the bronchiolar epithelium in CD-1 mice treated with TCE doses of 500 to 1000 mg/kg i.p. Immunohistochemical studies, using an antibody that recognizes dichloroacetyl lysine adducts, revealed dose-dependent formation of adducts in the bronchiolar epithelium. Localization of dichloroacetyl adducts in the Clara cells coincided with damage to this cell type in TCE-treated mice. Pretreatment of CD-1 mice with diallyl sulfone, an inhibitor of CYP2E1 and CYP2F2, abrogated the formation of the dichloroacetyl adducts and protected against TCE-induced bronchiolar cytotoxicity. Treatment of wild-type and CYP2E1-null mice with TCE (750 mg/kg i.p.) also elicited bronchiolar damage that correlated with the formation of adducts in the Clara cells. Immunoblotting, using lung microsomes from TCE-treated CD-1 mice, showed dose-dependent production of dichloroacetyl adducts that comigrated with CYP2E1 and CYP2F2. However, TCE treatment resulted in a loss of immunoreactive CYP2E1 and CYP2F2 proteins and p-nitrophenol hydroxylation, a catalytic activity associated with both cytochrome P450 enzymes. The TCE metabolite, chloral hydrate, was formed in incubations of TCE with lung microsomes from CD-1, wild-type, and CYP2E1-null mice. The levels were higher in CD-1 than in either wild-type or CYP2E1-null mice, although levels were higher in CYP2E1-null than in wild-type mice. These findings supported the contention that TCE bioactivation within the Clara cells, predominantly involving CYP2F2, correlated with bronchiolar cytotoxicity in mice.
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Trichloroethylene (C 2 HCl 3 ; TCE) is a nonflammable colorless liquid used extensively in vapor degreasing and cold cleaning of metal parts, and as a result, occupational exposures are associated with the automotive, aviation, and metals industries. It has been estimated that 3.5 million workers are exposed annually to TCE (National Toxicology Program, 1990) . Environmental release of TCE in the United States for the years 1988 to 1997 exceeded 345 million pounds (Toxics Release Inventory, U.S. Environmental Protection Agency, 2004; http://www.epa.gov/triexplorer/), leading to TCE becoming a major contaminant in soil and groundwater (Agency for Toxic Substances and Disease Registry, 1997 Registry, , 1999 .
Exposure to TCE produces toxic effects in a variety of tissues, including the liver, kidney, lung, nervous system, and reproductive tissues. Available data are mostly derived from studies in the liver and showed that the toxicities produced by TCE are mediated via its biotransformation to reactive metabolites capable of binding to protein (Kautiainen et al., 1997; Cai and Guengerich, 2000) . Other studies have identified the potential of TCE and its metabolites to induce T-cell activation and to promote autoimmunity (Gilbert et al., 2004) . The metabolism of TCE is mediated through conjugative and oxidative pathways, and the selectivity of the specific pathway is related to the target organ. The conjugative pathway is a minor one and is associated with the nephrotoxic effects of TCE. Initial conjugation with glutathione, which takes place mainly in the liver, produces S- (1,2-dichlorovinyl) glutathione, and subsequent metabolic steps, including transport and biotransformation, result in the formation of S-(1,2-dichlorovinyl)-L-cysteine, a metabolite linked to nephrotoxicity in rats (Elfarra et al., 1986; Dekant et al., 1990; Bruning and Bolt, 2000) . The major route of TCE metabolism in the liver is oxidation via the cytochrome P450 (P450) system, and P450 enzymes, including CYP2E1, CYP1A1/2, CYP2B1/2, and CYP2C11/6, have been implicated (Nakajima et al., 1990 (Nakajima et al., , 1992a Guengerich et al., 1991) . Chloral, TCE oxide, and dichloroacetyl chloride are initial metabolites generated from TCE oxidation. Available evidence suggested that chloral and TCE oxide are both derived from an oxygenated TCE-P450 intermediate (Miller and Guengerich, 1982; Cai and Guengerich, 2000) . Chloral is rapidly converted to chloral hydrate (CH) that then undergoes oxidation and reduction to form trichloroacetic acid and trichloroethanol, respectively (Green and Prout, 1985; Dekant et al., 1986) . Dichloroacetyl chloride, which is believed to be derived from the TCE oxide, undergoes decomposition to form dichloroacetic acid that can also be formed from dechlorination of trichloroacetic acid (Lash et al., 2000) . Thus, TCE exposure and metabolism yield several metabolites, including chloral, CH, dichloroacetic acid, trichloroacetic acid, trichloroethanol, and dichloroacetyl chloride. Although the assignment of a TCE metabolite to a specific toxic effect and/or to a specific tissue hast proven to be a complex issue, it has been proposed that trichloroacetic acid is associated with hepatotoxicity (Buben and O'Flaherty, 1985) , trichloroacetic acid and dichloroacetic acid with hepatocarcinogenicity (Bull et al., 2002) , and S-(1,2-dichlorovinyl)-L-cysteine with nephrotoxicity (Dekant et al., 1990; Bruning and Bolt, 2000) .
An additional target of TCE is the lung where exposure causes lung cytotoxicity that is manifested selectively in the Clara cells of the bronchiolar epithelium (Forkert, 1995) . Recent studies have implicated the P450 enzymes CYP2E1, CYP2F2, and CYP2B1 in bioactivation of TCE in murine lung (Forkert et al., 2005) . Kinetic analysis using recombinant P450 enzymes revealed that recombinant rat CYP2E1 metabolized TCE to CH with greater affinity than did recombinant rat CYP2F4, recombinant mouse CYP2F2, and recombinant CYP2B1. The catalytic efficiencies (V max /K m ) for TCE metabolism followed the rank order CYP2E1 Ͼ CYP2F4 Ͼ CYP2F2 Ͼ CYP2B1 (Forkert et al., 2005) . These findings suggested that CYP2E1 and CYP2F metabolized TCE to CH to the greatest extent, whereas CYP2B1 had a lesser catalytic role. CYP2E1 and CYP2F2 are expressed constitutively in murine lung, and because both are preferentially localized in the Clara cells (Buckpitt et al., 1995; Forkert, 1995) , manifestation of cell damage in this cell type as a result of TCE exposure raises a question whether the formation of reactive metabolites takes place within this cell type. Here, we have undertaken studies to test the hypothesis that bronchiolar epithelial damage is associated with TCE bioactivation within the Clara cells with involvement of CYP2E1 and CYP2F2. Immunochemical studies were carried out to determine formation of dichloroacetyl lysine (DAL) protein adducts, which were used as an in vivo marker of TCE metabolism. Our results showed that bronchiolar damage correlated with the formation of DAL protein adducts that were highly localized within the Clara cells. Furthermore, the findings suggested that bioactivation of TCE is mediated by CYP2E1 and CYP2F2, although CYP2F2 seems to have a more important role than CYP2E1 in the ensuing lung cytotoxicity in mice.
Materials and Methods
Chemicals and Reagents. The following chemicals were used: trichloroethylene (purity 99.5%) and 4-nitrocatechol (Aldrich Chemical Co., Montreal, QC, Canada); sodium pentobarbital (Somnotol) (MTC Pharmaceuticals, Hamilton, ON, Canada); diallyl sulfone (Color Your Enzyme; Bath, ON, Canada); paraformaldehyde and hydrogen peroxide (Fisher Scientific, Nepean, ON, Canada); avidin/ biotin, streptavidin, and rabbit anti-goat horseradish peroxidase (Zymed Laboratories, South San Francisco, CA); goat anti-rabbit horseradish peroxidase, acrylamide/BIS, polyvinylidene difluoride membrane, and chemiluminescence reagents (Immuno-star horseradish peroxidase substrate kit), stripping buffer (Restore Western Stripping Buffer), and protein assay dye (Bio-Rad, Hercules, CA); goat anti-mouse horseradish peroxidase (Jackson ImmunoResearch, West Grove, PA); bovine serum albumin, p-nitrophenol (PNP), 4-nitrocatechol, Ponceau S stain, 1,3-dibromopropane, and goat anti-rabbit biotin (Sigma-Aldrich, St. Louis, MO); and 3,3Ј-diaminobenzidene tetrahydrochloride (DakoCytomation California Inc., Carpinteria, CA). The anti-CYP2E1 polyclonal antibody was obtained from Oxford Biomedical (Hornby, ON, Canada). The antidichloroacetyl polyclonal antibody was donated by Dr. N. R. Pumford (University of Arkansas, Fayetteville, AR). The CYP2F1 antibody used as an analog for CYP2F2 was donated by Dr. G. S. Yost (University of Utah, Salt Lake City, UT) and has been shown in previous studies to cross-react with CYP2F2 (Simmonds et al., 2004a) .
Animal Treatment. Male CD-1 mice, weighing 25 to 28 g, were purchased from Charles River Canada (Montreal, PQ, Canada). They were maintained on a 12-h light/dark cycle and were provided with water and food (Mouse Diet 5015; PMI Nutrition International, Inc., Brentwood, MO) ad libitum. The mice were acclimatized to laboratory conditions for one week before being used for experiments. For the histopathologic and immunohistochemical studies, mice were treated with 500, 750, and 1000 mg/kg, i.p., TCE in corn oil and were sacrificed 4 h later. In the inhibition studies, mice were pretreated with diallyl sulfone (100 mg/kg) by gavage, treated with TCE (750 mg/kg i.p.) 2 h later, and were sacrificed 4 h after TCE treatment. The time of sacrifice was selected based on results from preliminary studies that showed maximal labeling for DAL protein adducts in the bronchiolar epithelium at this time point. In the immunoblotting studies, mice were treated with 250, 500, 750, and 1000 mg/kg, i.p., TCE and were sacrificed 4 h later. In the experiments to determine PNP hydroxylation, mice were treated with 50, 100, 250, 500, 750, and 1000 mg/kg, i.p., TCE and were sacrificed 4 h later. Mice were anesthetized with sodium pentobarbital (120 mg/kg, i.p.), and lung tissue was fixed and processed for immunohistochemistry and histopathology using methods described previously (Forkert, 1995) . In all experiments, control mice were treated with equivalent volumes of vehicle.
Wild-type and CYP2E1-null mice were obtained from a colony (mixed 129/Sv and C57BL) developed (Lee et al., 1996) at the National Cancer Institute, National Institutes of Health (Bethesda, MD), and were rederived and bred at Charles River Laboratories, Inc. (Wilmington, MA). Male mice weighing 22 to 35 g (2-3 months old) were quarantined at the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (Research Triangle Park, NC) for 1 week before use in temperature-and humidity-controlled rooms with a 12-h light/dark cycle. National Institutes of Health 31 rodent chow diet and tap water were provided ad libitum. All animal care and experimental procedures were performed according to the National Institutes of Health guidelines (National Institutes of Health, 1985) .
Histopathology. Lungs were fixed by tracheal instillation and vascular perfusion using procedures described previously (Forkert,
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at ASPET Journals on September 23, 2017 jpet.aspetjournals.org 1995). In brief, a cannula was inserted into the right ventricle and lung tissue was flushed with saline. After the removal of excess blood from the tissue, lungs were perfused with 4% paraformaldehyde in 0.1 M Sorensen's phosphate buffer (12.0 mM NaH 2 PO 4 , 69.0 mM Na 2 HPO 4 , pH 7.4). The lungs were also inflated with 0.3 ml of the fixative. Tissues were fixed overnight and were then dehydrated, cleared, and embedded in paraffin using standard procedures. Paraffin sections (5 m) were prepared from lung tissue and were stained with hematoxylin and eosin for histopathologic observation by light microscopy.
Immunohistochemical Localization of DAL Protein Adducts. Lung tissue was fixed as described for histopathology. Paraffin sections (5 m) were prepared and adhered to glass slides. Identification of DAL proteins in tissue sections was performed using an anti-DAL antibody (1:500) and the avidin-biotin complex technique. The sections were deparaffinized, cleared and hydrated in a graded ethanol series. The sections were rinsed in phosphate-buffered saline (PBS) and treated with 5% normal goat serum to block nonspecific antibody binding. The sections were then incubated for 60 min with the anti-DAL antibody (1:200) diluted in PBS containing 2.5% normal goat serum. After thorough rinsing in PBS, tissue sections were reacted for 30 min with a biotinylated goat anti-rabbit antibody. Endogenous peroxidase activity was inhibited by incubating tissue sections with 1% hydrogen peroxide in water for 30 min. Sections were then reacted for 10 min with streptavidin conjugated to horseradish peroxidase, and the immunoperoxidase color reaction developed by reaction with 0.05% 3,3Ј-diaminobenzidine tetrahydrochloride and 0.01% hydrogen peroxide. The sections were then rinsed, incubated for 5 min in 0.15 M sodium chloride containing 0.5% copper sulfate, dehydrated, cleared, and mounted. Controls for the specificity of the immunohistochemical reactions included incubations performed in the absence of the anti-DAL antibody.
Preparation of Microsomes. Lung tissues from 30 mice were pooled for each lung microsomal sample. Microsomes were prepared by differential centrifugation as described previously (Simmonds et al., 2004b) , with minor modifications. Lung tissue was minced and homogenized in 4 volumes of cold phosphate-buffered KCl (139 mM KCl, 100 mM K 2 HPO 4 , 1.5 mM EDTA, pH 7.4). The homogenate was subjected to centrifugation at 12,000g for 20 min at 2°C. The supernatant was then centrifuged at 105,000g for 60 min. The pellet was homogenized using three strokes of the pestle, and the resulting homogenate was centrifuged at 12,500g for 60 min. The final pellet was homogenized using 400 l of buffer and a hand-held pestle. Microsomes were also prepared from the lungs of wild-type and CYP2E1-null mice; tissues from 30 mice each were pooled for each microsomal sample. Aliquots of lung microsomes were frozen in liquid nitrogen and stored at Ϫ70°C. Microsomal protein concentrations were determined by the dye-binding protein assay, using bovine serum albumin as the standard.
Protein Immunoblotting. Protein blots were prepared using a modification of procedures described previously (Forkert, 1995) . Microsomal proteins were separated by SDS-PAGE, using an 8.5% gel, and were then transferred to a polyvinylidene difluoride membrane. Microsomal proteins from human ␤-lymphoblastoid cells containing a CYP2F1 insert were included to serve as a positive control for the CYP2F2 protein. Low-range SDS-PAGE standards (Bio-Rad) were included with each gel. The membrane was stained next with Ponceau S (Sigma-Aldrich) to confirm uniform protein loading and transfer to the membrane. The membrane was incubated overnight in a blocking solution consisting of 10% nonfat milk powder in 20 mM Tris-Tris-HCl containing 500 mM NaCl, pH 7.5. After rinsing, the membrane was incubated for 2 h with a CYP2F1, CYP2E1, or anti-DAL antibody. The CYP2F1 antibody was affinity-purified using a SulfoLink Coupling gel kit (Pierce Chemical, Rockford, IL), and the anti-DAL antibody was purified using an Immunopure IgG purification kit (Pierce Chemical). The blots were incubated in a horseradish peroxidase-conjugated secondary antibody for 2 h as follows: CYP2F1 and anti-DAL with goat-anti-rabbit-IgG (1:18,000) and CYP2E1 with rabbit-anti-goat-IgG (1:5000). The protein bands were visualized using chemiluminescence reagents (Immuno-Star horseradish peroxidase substrate kit). The blots were then stripped using Restore Western Stripping buffer (Pierce Chemical) for 15 min at 37°C. Initially, the efficiency of the stripping was assessed by incubating the membrane with the goat anti-rabbit IgG conjugated to horseradish peroxidase (1:1500) and reacting with the chemiluminescence detection reagents. The absence of protein bands indicated that the stripping was successful. The stripped membrane was incubated overnight at 4°C with the CYP2E1 polyclonal antibody (1: 500), the CYP2F1 polyclonal antibody (1:1500), or the anti-DAL antibody (1:500). After rinsing in Tris-buffered saline containing Tween 20, the membrane was incubated for 2 h with a rabbit antigoat antibody conjugated to horseradish peroxidase. The protein bands were visualized by reaction with chemiluminescence detection reagents. Densitometric scanning and analysis of the protein bands in the gels were performed using Kodak 1D Image Analysis Software (Sigma-Aldrich).
Enzyme Assays. Hydroxylation of PNP was used as a marker for both CYP2E1 and CYP2F2 catalytic activity (Shultz et al., 1999; Simmonds et al., 2004a) . Reaction mixtures contained lung microsomal proteins (0.5 mg) from mice treated with TCE (50 -1000 mg/kg i.p.) and NADPH (1.5 mM). After preincubation for 3 min at 37°C, PNP (1 mM) in dimethyl sulfoxide was added and the incubations were continued for an additional 10 min. Microsomal proteins were precipitated with perchloric acid (70%, 20 l) and removed by centrifugation. Quantification of PNP in the supernatant fraction was determined by HPLC analysis as described previously (Duescher and Elfarra, 1993) . In brief, samples (100 l) were analyzed using a Beckman System Gold Programmable Solvent Module 126 HPLC, a reversed-phase C 18 column (5 m, 4.6 ϫ 250 mm; Beckman Ultrasphere ODS) and a Beckman System Gold Module 168 UV detector (Beckman Coulter, Fullerton, CA). The isocratic mobile phase was 25% acetonitrile/75% H 2 O/0.1% trifluoroacetic acid with a flow rate of 1.5 ml/min. The column effluent was monitored at 345 nm. Levels of PNP hydroxylase activity were assessed by the formation of 4-nitrocatechol, which eluted from the column at 5.5 min, and quantified by relating peak area to a standard calibration curve of known amounts of 4-nitrocatechol.
Formation of Chloral Hydrate in Lung Microsomal Incubations. Reaction mixtures in a total volume of 500 l of 50 mM Tris-HCl buffer, pH 7.4, consisted of lung microsomal proteins (0.25 mg) from untreated mice, NADPH (1.0 mM), and TCE (0.25-5 mM) in acetonitrile (0.4%, v/v). The incubations were performed at 37°C for 20 min, and the reactions were terminated by freezing in liquid nitrogen. Detection of CH was determined using the method described previously (Cummings et al., 2001) . Samples (250 l) were thawed and extracted with ethyl acetate (0.5 ml) after which 1,2-dibromopropane (10 nmol) was added as an internal standard. Analysis for TCE and CH was performed by gas chromatography with electron capture detection, using a PerkinElmer PE-210 capillary column (30 m ϫ 0.25 mm i.d. ϫ 0.5 m film thickness) and a PerkinElmer AutoSystem XL GC system (PerkinElmer Life and Analytical Sciences, Boston, MA). Injector temperature was 200°C, detector temperature was 300°C, and helium was the carrier at a flow rate of 24.8 ml/min at 150°C. Oven temperature was maintained at 35°C for 11 min followed by a linear increase from 35 to 120°C in 8 min with a final holding temperature of 120°C for an additional 19 min. Retention times for TCE and CH were 3.90 and 6.15 min, respectively. Limits of detection were 0.2 and 0.05 pmol/mg protein for TCE and CH, respectively. TCE, structural alterations at 4 h consisted of a few Clara cells with pyknotic nuclei that were in the process of exfoliation (Fig. 1B) . The epithelial injury was exacerbated after exposure to a TCE dose of 750 mg/kg and was characterized by disruption of the epithelium; the Clara cells appeared distorted, were sloughed, or were in the process of losing their apices (Fig. 1C) . Treatment of mice with 1000 mg/kg produced more severe cytotoxicity with segments of the bronchiole that were denuded of epithelium and with exfoliated epithelial cells present in the airway lumen (Fig. 1D) . Damage was not apparent in the alveolar type II cells after treatment with any TCE dose.
In the inhibitory studies, treatment of CD-1 mice with TCE (750 mg/kg i.p.) alone exhibited morphologic features indicative of disintegration as in the histopathologic studies described previously (Figs. 1C and 3A) . In CD-1 mice that were pretreated with DASO 2 2 h before TCE treatment, the bronchiolar epithelium appeared intact and contained numerous Clara cells that exhibited normal characteristics (Figs. 1C  and 3E ).
In CYP2E1-null mice treated with 750 mg/kg TCE, many Clara cells seemed to have undergone exfoliation and/or lost their apices so that the residual epithelium appeared flattened and markedly less substantial than in untreated mice (Fig. 3E) . The extent of damage in CYP2E1-null mice was slightly more severe than in wild-type mice treated with the same TCE dose (data not shown). The Clara cell lesion was also more severe in CYP2E1-null than in CD-1 mice treated with the 750 mg/kg TCE dose (Figs. 1C and 3A) .
Localization of DAL Protein Adducts. Immunohistochemical studies were performed on lung tissue sections from TCE-treated CD-1, wild-type, and CYP2E1-null mice. A polyclonal anti-DAL antibody was used for these studies. Positive labeling for the DAL protein adducts was observed in the bronchiolar epithelium of CD-1 mice (Fig. 2) . The labeling was prominent in the Clara cells and was concentrated within their cellular apices (Fig. 2, B and C) . The extents of labeling were dose-dependent and were more abundant in lung sections from mice treated with 1000 mg/kg TCE (Fig.  2D ) than in those treated with doses of 500 and 750 mg/kg (Fig. 2, B and C) . Dose-dependent formation of the protein adducts was also found in alveolar type II cells (Fig. 2, B-D) . The labeling was not visualized in lung sections from untreated mice reacted with the anti-DAL antibody ( Fig. 2A) or in sections from TCE-treated mice that were not reacted with the anti-DAL antibody (data not shown).
In the inhibition studies, labeling for the DAL protein adducts was seen in the bronchiolar epithelium and Clara cells of CD-1 mice treated with only TCE (750 mg/kg i.p.) (Fig. 3C) . In mice pretreated with DASO 2 2 h before TCE treatment, immunoreactivity for the DAL adducts was minimal and was similar to that in untreated mice (Fig. 3D) .
Labeling was not observed in lung tissue from either wild-type or CYP2E1-null mice that were untreated (data not shown). In CYP2E1-null mice treated with TCE (750 mg/kg), labeling for the DAL adducts was observed in the bronchiolar epithelium, but the immunoreactivity seemed less pronounced than in CD-1 mice treated with the same TCE dose, due in part to attenuation of the epithelium and loss of Clara cells in the null mice (Fig. 3F) . The labeling was also seen in the lungs of TCE-treated wild-type mice (data not shown).
Protein Immunoblotting. Protein blots were prepared with lung microsomal proteins from mice treated with various doses of TCE (250, 500, 750, and 1000 mg/kg). The anti-DAL antibody detected a major protein band of approximately 51 kDa in the lung microsomal proteins (Fig.  4A) . The immunoreactivities of the DAL protein adducts were dose-dependent and were incremental with microsomal proteins from mice treated with increasing doses of TCE. When the blot was stripped and subsequently reprobed with a CYP2E1 antibody, a protein band of 51 kDa was also visualized (Fig. 4B) . Immunodetectable CYP2E1 protein was highest in lung microsomes from untreated mice but was virtually abolished in microsomes from mice treated with all TCE doses (Fig. 4B) . Staining with Ponceau S showed that the loading of microsomal proteins from mice subjected to different treatment regimens was similar (Fig. 4C) .
Additional protein blots were prepared with lung microsomal proteins from control and TCE-treated mice using the anti-DAL antibody. The DAL protein adducts were visualized as a band with a molecular mass of 56 kDa and confirmed to have dose-dependent immunoreactivities in mice treated with TCE doses ranging from 250 to 1000 mg/kg (Fig. 5A) . Loading of the microsomal proteins, as assessed by Ponceau S staining, was comparable in all of the lung samples (Fig.  5C ). When the blots were stripped and reacted with the anti-CYP2F1 antibody, CYP2F2 was recognized as a protein band of approximately 56 kDa, although the control consisting of ␤-lymphoblastoid microsomes containing a CYP2F1 insert migrated at a slightly more rapid rate than the (Fig. 5B) . The CYP2F2 protein was present in lung microsomes from untreated mice (Fig. 5B) . However, treatment of mice with TCE resulted in a loss of immunodetectable CYP2F2 protein in lung microsomes from mice treated with doses of TCE ranging from 250 to 1000 mg/kg (Fig. 5B) . (A-D) . A, in TCE-treated CD-1 mice, the bronchiolar epithelium appeared attenuated and the airway lumen contained detached epithelial cells (arrowheads). B, in CD-1 mice pretreated with DASO 2 , the bronchiolar epithelium contained normal Clara cells (arrowheads). Labeling for DAL protein adducts in CD-1 mice was concentrated in the bronchiolar epithelium (C) and was absent in mice pretreated with DASO 2 (D). E, in TCE-treated CYP2E1-null mice, Clara cells were damaged, resulting in flattening of the epithelium (arrow) and the presence of cell debris in the airway lumen (arrowheads). F, labeling for DAL protein adducts was localized in the bronchiolar epithelium and in residual Clara cells (arrowheads). Tissue sections for histopathology were stained with hematoxylin and eosin, and immunohistochemistry was performed using an anti-DAL polyclonal antibody and the avidin-biotin complex procedure. Scale bars: 20 m (A-F).
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Microsomal PNP Hydroxylation. Treatment of mice with 50 mg/kg TCE caused a precipitous decline (63% of control) in lung microsomal PNP hydroxylase activity (Fig.  6 ). Further decreases of 76 and 80% were detected when mice were treated with TCE at doses of 100 and 250 mg/kg, respectively. The nadir was reached at 500 mg/kg when residual levels comprised only 8% of the control level. No further decreases in hydroxylase activity were observed at TCE doses of 750 or 1000 mg/kg. There was no loss of enzyme activity in lung microsomes from control mice treated with corn oil.
Formation of Chloral Hydrate in Lung Microsomal Incubations. Formation of CH was determined in incubations of TCE with lung microsomes from male CD-1, wildtype, and CYP2E1-null mice. In CD-1 mice, rates of CH production were linear in microsomal incubations containing 0.25 to 3.0 mM TCE (Fig. 7A) . Saturation was achieved at 3.0 mM, as no further increase in the rates of CH formation was found in incubations containing 5.0 mM TCE. In wild-type and CYP2E1-null mice, the rates of CH formation were almost identical in microsomal incubations containing 0.25 to 0.75 mM TCE (Fig. 7B) . However, the rates of CH production differed in wild-type and CYP2E1-null mice at higher TCE concentrations. The peak rates of CH formation in wild-type mice were achieved at a TCE concentration of 0.75 mM, with declines occurring at concentrations of 1.0 and 2.0 mM. In CYP2E1-null mice, peak rates of CH formation were achieved at 1.0 mM TCE and were lower in incubations containing a concentration of 2.0 mM. A plateau in the rates of CH formation in lung microsomes from wild-type and CYP2E1-null mice was observed in incubations with TCE concentrations of 2.0 to 5.0 mM. Hence, saturation in the rates of CH production in wild-type mice (0.75 mM) occurred at a lower TCE concentration than in CYP2E1-null mice (1.0 mM), and both concentrations were substantially lower than that for CD-1 mice (3.0 mM). Formation of CH was absent or minimal in control incubations performed in the absence of NADPH or TCE.
Discussion
The vulnerability of the Clara cells to chemically induced cytotoxicity has been ascribed to their substantial content of cytochrome P450 enzymes capable of mediating the bioactivation of substrates to reactive metabolites that elicit cellular toxicities. Early studies have identified Clara cell and bron- Fig. 4 . Effect of TCE dose on formation of DAL protein adducts (A) and expression of CYP2E1 (B) in lung microsomes from TCE-treated CD-1 mice. Mice were treated with TCE at doses ranging from 250 to 1000 mg/kg and were sacrificed 4 h after treatment. Control mice were treated with corn oil. C, lung microsomal proteins were separated by SDS-PAGE, transferred to a membrane, and stained with Ponceau S. The microsomal proteins were probed with an anti-DAL antibody, and the membrane was stripped and reprobed with an anti-CYP2E1 antibody. A major band of 51 kDa was detected for both the DAL protein adduct (A) and CYP2E1 (B). Lanes 1 and 2, control; lane 3, 250 mg/kg; lane 4, 500 mg/kg; lane 5, 750 mg/kg; lane 6, 1000 mg/kg TCE. Fig. 5 . Effect of TCE dose on formation of DAL protein adducts (A) and expression of CYP2F2 (B) in lung microsomes from TCE-treated CD-1 mice. Mice were treated with TCE (250, 500, 750, and 1000 mg/kg i.p.) and were sacrificed 4 h after treatment. Control mice were treated with corn oil. Lung microsomal proteins were separated by SDS-PAGE, transferred to a membrane, and stained with Ponceau S (C) to control for protein loading. The microsomal proteins were probed with an anti-DCA antibody, and the membrane was stripped and reprobed with an anti-CYP2F1 antibody. A major band of 56 kDa was detected for both the DAL protein adduct (A) and CYP2F2 (B). Lanes 1 and 2, control; lane 3, 250 mg/kg; lane 4, 500 mg/kg; lane 5, 750 mg/kg; lane 6, 1000 mg/kg TCE. Fig. 6 . Dose-dependent effects on rates of PNP hydroxylation in lung microsomes from TCE-treated CD-1 mice. Mice were treated with TCE (50, 100, 250, 500, 750, and 1000 mg/kg i.p.) and were sacrificed 4 h after treatment. Reaction mixtures consisted of microsomal protein (0.5 mg) and NADPH (1.5 mM) in a total volume of 250 l of potassium phosphate buffer (100 mM), pH 6.8, containing ascorbic acid (0.1 mM). Hydroxylation of PNP was estimated from formation of 4-nitrocatechol and determined by HPLC analysis as described under Materials and Methods. Data are expressed as mean Ϯ S.D. of quadruplicate determinations. (Forkert et al., 1985) . More recent studies have yielded data supporting the involvement of CYP2E1, CYP2F2, and CYP2B1 in mediating TCE metabolism to CH (Forkert et al., 2005) . Since CYP2E1 and CYP2F2 are highly concentrated in the Clara cells (Buckpitt et al., 1995; Forkert, 1995) , we postulated that bioactivation of TCE takes place within the target cell population, leading to the selective damage of the Clara cells. The formation of DAL protein adducts was used as an in vivo marker of TCE metabolism and was identified immunochemically using an antiserum directed against dichloroacetic anhydride-modified rabbit serum albumin (Halmes et al., 1996; Griffin et al., 1998) . Binding of the antibody to TCE adducts on immunoblots of liver microsomes was completely inhibited by N ⑀ -(dichloroacetyl)-L-lysine, indicating that the antibody recognized DAL residues on proteins. The formation of N 6 -(dichloroacetyl)lysine from TCE metabolism has been confirmed in studies using liver microsomal incubations and bovine serum albumin as the model protein (Cai and Guengerich, 2000) . Our immunohistochemical studies in TCE-treated CD-1 mice showed formation of DAL protein adducts that were highly localized in the Clara cells of the bronchiolar epithelium (Fig. 2) . The formation of the DAL protein adducts was dose-dependent, as the magnitudes of labeling were incremental in mice treated with 500 to 1000 mg/kg TCE (Fig. 2, B-D) . The severities of Clara cell damage were dose-dependent and were most pronounced in mice treated with 1000 mg/kg TCE (Fig. 1D) . In CYP2E1-null mice treated with 750 mg/kg TCE, labeling for the DAL protein adducts was also highly localized in the bronchiolar epithelium and in the Clara cells (Fig. 3F ) and coincided with damage to this cell type (Fig. 3E) . These results affirmed the coincidental localization of DAL protein adducts and cell damage in the bronchiolar epithelium and supported the assumption that the cytotoxic effects are mediated via TCE metabolism within the target Clara cells. However, it should be noted that dose-dependent formation of DAL protein adducts was also found in alveolar type II cells (Fig. 2 , B-D), although cell injury was not apparent. This observation suggested that there may be a threshold in adduct formation and hence bioactivation at which toxicity is manifested. The dose-dependent formation of DAL protein adducts in the lungs of CD-1 mice indicated that dichloroacetyl chloride was generated from TCE in this tissue. Moreover, there was dose-dependent production of CH in incubations of CD-1 lung microsomes with TCE (Fig. 7A) . A question arises regarding which TCE metabolite(s) represents the reactive species. It has been proposed that accumulation of chloral within the Clara cells is responsible for their susceptibility to TCEinduced cytotoxicity (Odum et al., 1992) . This accumulation has been ascribed to diminished metabolism of chloral to trichloroethanol and its glucuronide. Furthermore, treatment of mice with chloral produced a Clara cell lesion similar to that induced by TCE. Other studies have shown that, although murine lung microsomes were able to metabolize TCE to chloral at a significant rate, the rate in rat lung was 23-fold lower (Green et al., 1997) . It has been proposed that the differing capabilities for chloral formation in mice and rats are associated with the development of lung tumors in mice but not in rats exposed to TCE by inhalation (Fukuda et al., 1983; Maltoni et al., 1986; Green, 2000) . Although plausible, direct evidence for this proposed mechanism is lacking. However, our finding of relatively more severe bronchiolar damage in CYP2E1-null mice (Fig. 3E ) coupled with diminished rates of CH formation (Fig. 7) compared with those in CD-1 mice argues against chloral as the proximate toxicant. Whether dichloroacetyl chloride and/or other metabolite(s) play a pertinent role in TCE-induced lung cytotoxicity and/or carcinogenicity remains to be established. In the context of carcinogenicity, it is of interest to identify the cell of origin of the lung tumors to verify if it coincides with the cell type in which TCE bioactivation takes place.
Previous studies have reported that a reactive intermediate formed from TCE metabolism binds to a 50-kDa protein in murine liver that has been postulated to be CYP2E1 (Griffin et al., 1998) . A subsequent investigation using rat hepatocytes exposed to TCE demonstrated the presence of a similar 50-kDa protein that comigrated with CYP2E1 (Griffin et al., 1998) . This 50-kDa protein was not detected in human hepatocytes, but instead a 47-kDa protein that did not comigrate with CYP2E1 was identified, suggesting that the P450 isoforms that metabolized TCE differ in rats versus humans. These data suggested that TCE metabolism by CYP2E1 produces a dichloroacetyl metabolite that binds to the CYP2E1 apoprotein at the site of formation. In this investigation, studies were performed to further explore this concept in murine lung. Since CYP2E1 and CYP2F2 mediated bioactivation of TCE in the lung, formation of a reactive species that binds to the apoprotein moieties of these P450 enzymes should generate protein adducts with gel mobilities similar to those for CYP2E1 and CYP2F2, although it is probable that multiple proteins may exhibit similar gel mobilities. Immunoblots prepared using lung microsomes and the anti-DAL antibody demonstrated that TCE treatment yielded protein bands of 51 kDa exhibiting dose-dependent immunoreactivities for doses ranging from 250 to 1000 mg/kg (Figs. 4 and 5) . When the blots were stripped and reprobed with either an anti-CYP2E1 or an anti-CYP2F1 antibody, immunodetectable protein bands corresponding to those for the DAL adducts were visualized (Figs. 4 and 5) . In both cases, CYP2E1 and CYP2F2 were constitutively expressed and TCE treatment caused loss of protein content of both P450 enzymes, indicating treatment-related modification of CYP2E1 and CYP2F2 protein structures. These findings suggested that a reactive TCE metabolite, including dichloroacetyl chloride, was formed capable of binding to both P450 proteins and rendering the epitopes unrecognizable by the antibody. Moreover, the P450 enzymes were catalytically inactivated, as there was dose-dependent loss of PNP hydroxylation, an enzyme catalytic activity shown to be associated with both CYP2E1 and CYP2F2 (Shultz et al., 1999; Simmonds et al., 2004a) . The involvement of CYP2E1 and CYP2F2 is supported by the results of in vivo inhibitory studies with DASO 2 , a garlic compound that has been shown to inhibit CYP2E1 and CYP2F2 (Simmonds et al., 2004a) . Pretreatment of mice with DASO 2 2 h before TCE inhibited the formation of DAL protein adducts and protected from bronchiolar cytotoxicity (Fig. 3, A and B) . Taken together, these findings are consistent with a role for CYP2E1 and CYP2F2 in TCE metabolism in murine lung.
Previous studies using recombinant P450 enzymes suggested that CYP2E1 is a major isoform mediating TCE metabolism (Forkert et al., 2005) . On the basis of these findings, we postulated that treatment of CYP2E1-null mice with TCE should result in diminution of both bronchiolar cytotoxicity and production of DAL adducts compared with the effects in wild-type mice. In addition, incubations of TCE with lung microsomes from CYP2E1-null mice should result in decreased rates of CH production indicative of reduced TCE metabolism. Surprisingly, our results showed that bronchiolar damage and formation of DAL protein adducts were undiminished in the lungs of CYP2E1-null mice (Fig. 3, E and  F) . Moreover, the generation of CH from TCE in incubations of lung microsomes from CYP2E1-null mice was achieved at rates that were higher than in wild-type mice (Fig. 7B) . These findings suggested that CYP2F2 has a more important role than CYP2E1 in TCE metabolism in murine lung, and these data differed from those derived from studies using recombinant P450 enzymes (Forkert et al., 2005) . Recombinant rat CYP2E1 (V max /K m ϭ 0.79) demonstrated greater catalytic affinity and efficiency for TCE metabolism than did recombinant CYP2F2 (V max /K m ϭ 0.11), suggesting that TCE metabolism in rats and mice may differ and may be mediated mainly by CYP2E1 in rats and CYP2F2 in mice. However, the higher rates of CH production by lung microsomes from CYP2E1-null mice compared with rates in wild-type mice may not be mediated entirely by CYP2F2. Compensatory up-regulation of P450 enzymes involved in TCE metabolism and/or recruitment of other P450 enzymes might also be responsible for the outcome in the lungs of CYP2E1-null mice. In this regard, studies of protein content and catalytic activities of CYP2E1 and CYP2F2 as well as those of other P450 enzymes in wild-type and CYP2E1-null mice are particularly needed to characterize their metabolic status under conditions of gene disruption.
In summary, the results of this study are consistent with the contention that bronchiolar damage induced by TCE is associated with its bioactivation within the target Clara cells. Furthermore, the findings supported the involvement of CYP2E1 and CYP2F2 in TCE metabolism, although CYP2F2 seems to have a more important role than CYP2E1 in murine lung.
